PHASE

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Retrieved on: 
Monday, August 2, 2021
Health sciences, Medicine, Clinical medicine, Zoonoses, Infectious diseases, Nose, Dosage forms, Pandemics, Virus, COVID-19, Nasal spray

It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.

Key Points: 
  • It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.
  • Available in the form of a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
  • SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORS) to treat and prevent microbial infections in 2017.
  • Available at https://www.clinicaltrialsarena.com/news/sanotize-nasal-spray-reduces-co...
    2 SaNOtize's "revolutionary" Covid-19 nasal spray bolstered by Phase II trial data.

Global Immersion Cooling Market (2021 to 2026) - Adoption in Low-Density Data Centers Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Technology, Engineering, Hardware, Manufacturing, Thermodynamics, Immersion cooling, Mechanical engineering, Physical sciences, Coolant, PHASE, Heating, ventilation, and air conditioning, Dielectrics, Liquid dielectrics, Organofluorides, Computer cooling

Single-phase type segment is projected to lead the immersion cooling market during the forecast period.

Key Points: 
  • Single-phase type segment is projected to lead the immersion cooling market during the forecast period.
  • Based on type, the single-phase immersion cooling is estimated to grow at the highest CAGR during the forecasted period.
  • In single-phase immersion cooling, the coolant never changes state, i.e., it never boils or freezes and always remains in a liquid form.
  • Due to this, there are no chances of the cooling fluid getting evaporated as it does in two-phase immersion cooling technique.

P.volve Launches a First to Market Clinically Backed Program Revolutionizing Women's Wellness Through Nutrition and Exercise Tied to Menstrual Phases

Retrieved on: 
Monday, July 26, 2021
Quality of life, Wellness

NEW YORK, July 26, 2021 /PRNewswire/ --Omni-channel dynamic fitness method, P.volve , today announces its newest women's health and wellness program - Phase & Function.

Key Points: 
  • NEW YORK, July 26, 2021 /PRNewswire/ --Omni-channel dynamic fitness method, P.volve , today announces its newest women's health and wellness program - Phase & Function.
  • Phase & Function launches as a clinically backed, first-to-market program, with dedicated cycle tracking, a personalized workout, and nutrition plan, as well as expert-led education.
  • The team of experts have also conducted live Q&A sessions as an added information resource online (via desktop and mobile web).
  • She is certified in Adult Weight Management Levels I & II and is well versed in both the clinical and private space.

P.volve Launches a First to Market Clinically Backed Program Revolutionizing Women's Wellness Through Nutrition and Exercise Tied to Menstrual Phases

Retrieved on: 
Monday, July 26, 2021

NEW YORK, July 26, 2021 /PRNewswire/ -- Omni-channel dynamic fitness method, P.volve, today announces its newest women's health and wellness program - Phase & Function.  Combining movement, mind, and meals, Phase & Function is powered by periods, with information and ideas to help women harness the four phases of the menstrual cycle to look and feel amazing. It is uniquely designed to help women get their bodies to work as they naturally should and revolutionizes the management of traditional menstrual symptoms like PMS and PMDD through dedicated and personalized nutrition and exercise plans created to sync with the four phases of the menstrual cycle.

Key Points: 
  • Phase & Function launches as a clinically backed, first-to-market program, with dedicated cycle tracking, a personalized workout, and nutrition plan, as well as expert-led education.
  • The team of experts have also conducted live Q&A sessions as an added information resource online (via desktop and mobile web).
  • This first-to-market approach is the next phase of cycle syncing to work with your body and feel empowered all month long.
  • She is certified in Adult Weight Management Levels I & II and is well versed in both the clinical and private space.

Gilbert Family Foundation Collaborates with the Children's Oncology Group and Children's Hospital of Philadelphia to Validate a New Tool to Measure Progressive Vision Loss

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Medicine, Clinical medicine, Oncology, Neurofibromin 1, Proteins, NF1, Biomarker, Malignancy

NF1 is a multisystem genetic disorder characterized primarily by the growth of benign and malignant nervous system tumors.

Key Points: 
  • NF1 is a multisystem genetic disorder characterized primarily by the growth of benign and malignant nervous system tumors.
  • This becomes particularly challenging with younger patients, meaning there is a great need for a more reliable, quantitative biomarker for vision loss.
  • Robert Avery and Michael Fisher at Children's Hospital of Philadelphia (CHOP), this study is an exploratory aim of the ongoing Children's Oncology Group Phase III randomized clinical trial ACNS1831 ( NCT03871257 ).
  • For more information on the Gilbert Family Foundation, please visit gilbertfamilyfoundation.org .

As Part of a Global Partnership with Nestlé Health Science, VALBIOTIS Initiates the Pivotal Late Stage Development Phase of TOTUM-63, a Plant-Derived Active Substance With Clinically Demonstrated Metabolic Health Benefits in People With Prediabetes

Retrieved on: 
Thursday, April 2, 2020
Health, Diabetes, Infectious diseases, Clinical trials, Research, Science, Biotechnology, Health, Articles, Clinical research, PHASE, Clinical trial

This last phase of the clinical development was co-designed with Nestl Health Science's medical and regulatory teams and consists of one pivotal Phase II/III clinical study, called REVERSE-IT.

Key Points: 
  • This last phase of the clinical development was co-designed with Nestl Health Science's medical and regulatory teams and consists of one pivotal Phase II/III clinical study, called REVERSE-IT.
  • It will be entirely funded by the partnership signed in February 2020 with Nestl Health Science.
  • Murielle CAZAUBIEL, Head of Development and Medical Affairs, states: The REVERSE-IT study results from the combined expertise of VALBIOTIS and Nestl Health Science.
  • In 2020, VALBIOTIS has signed a global and long-term partnership with Nestl Health Science for the development and worldwide commercialization of TOTUM-63.

Worldwide Clinical Trials Expands Executive Team with Key New Hire, Mike Mencer as EVP and General Manager, Early Phase Services

Retrieved on: 
Wednesday, February 19, 2020
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Health, Articles, Clinical research, Clinical pharmacology, Design of experiments, PHASE, Clinical trial

Mikes passion for optimization and operational excellence is well suited to our Early Phase team.

Key Points: 
  • Mikes passion for optimization and operational excellence is well suited to our Early Phase team.
  • We are beyond thrilled to have him on board to move our Phase I team forward, said Peter Benton, president and COO, Worldwide Clinical Trials.
  • Mencer enlists with Worldwide following his position as executive director of BD operations at Advanced Enrollment Solutions.
  • From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.

Phase Four Names Laura Overly President

Retrieved on: 
Tuesday, January 28, 2020
Physical sciences, Natural sciences, Physics, Supply chain management, Spacecraft propulsion, Astrophysics, Gases, Plasma, Supply chain, PHASE

EL SEGUNDO, Calif., Jan. 28, 2020 /PRNewswire/ -- Phase Four, makers of radio frequency (RF) plasma engines for in-space propulsion, today announced the appointment of Laura Overly as President, effective immediately.

Key Points: 
  • EL SEGUNDO, Calif., Jan. 28, 2020 /PRNewswire/ -- Phase Four, makers of radio frequency (RF) plasma engines for in-space propulsion, today announced the appointment of Laura Overly as President, effective immediately.
  • As President, Overly will oversee Phase Four's core operations, including supply chain, manufacturing, human resources, legal, finance, and business and product development.
  • Overly joined Phase Four in 2018 as its director of supply chain, overseeing key business development and supply chain functions.
  • I'm excited to continue building a strong, diverse future in space with Laura and the Phase Four team," said Beau Jarvis, CEO.

G&W Electric Introduces its Model Based Single Phase FLISR at DistribuTECH 2020

Retrieved on: 
Tuesday, January 28, 2020
Articles, Engineering, Electric power distribution, Electromagnetism, Software quality, AC power, Single-phase electric power, Reliability engineering, PHASE

BOLINGBROOK, Ill., Jan. 28, 2020 /PRNewswire/ -- G&W Electric Co. , a global supplier of electric power equipment since 1905, today announced the debut of its new Single Phase Fault Location, Isolation and Service Restoration (FLISR) at DistribuTECH International2020.

Key Points: 
  • BOLINGBROOK, Ill., Jan. 28, 2020 /PRNewswire/ -- G&W Electric Co. , a global supplier of electric power equipment since 1905, today announced the debut of its new Single Phase Fault Location, Isolation and Service Restoration (FLISR) at DistribuTECH International2020.
  • The first Model Based Single Phase FLISR available on the market will be on display at booth 2623 where the company will be conducting live demonstrations.
  • The new Single Phase FLISR serves as an additional option to further improve reliability indices by only isolating the single phase that is affected by a fault.
  • By providing greater visibility into outages, the new single phase FLISR allows utilities to automatically reroute power, minimizing the number of customers impacted by outages.

Stellar Solutions Wins Phase 2 Award in $1.2M National Geospatial-Intelligence Agency Competition

Retrieved on: 
Monday, September 30, 2019
QuakeFinder, Stellar, PHASE, Sol, National Geospatial-Intelligence Agency, Computing, Articles, Computer data

Stellar had previously been named one of 10 winners in Phase 1 of the $1.2 million National Geospatial-Intelligence Agency (NGA) global open innovation challenge that was launched in March.

Key Points: 
  • Stellar had previously been named one of 10 winners in Phase 1 of the $1.2 million National Geospatial-Intelligence Agency (NGA) global open innovation challenge that was launched in March.
  • Phase 2 was open to solvers from the first phase as well as new entrants, and sought detailed designs and plans for data collection methodologies.
  • An independent panel helped select Stellar's Quakefinder team proposal as one of five Phase 2 winners that each will receive $200,000 in cash prizes.
  • "This award provides important validation of the expertise and value of the team responsible for Stellar Solutions' humanitarian research & development program, QuakeFinder.